Status:
COMPLETED
Mirtazapine in Alzheimer-associated Weight Loss
Lead Sponsor:
Brugmann University Hospital
Conditions:
Alzheimer's Disease
Weight Loss
Eligibility:
All Genders
Brief Summary
Weight loss is a frequent problem associated with Alzheimers disease (AD). Mirtazapine has weight loss as a frequent side effect. The aim of this retrospective study is to check whether mirtazapine 3...
Eligibility Criteria
Inclusion
- AD or mixed dementia
- documented weight loss
- mirtazapine 30 mg explicitly prescribed against weight loss
Exclusion
- no treatment compliance
- other causes of weight loss
- other interventions against weight loss
Key Trial Info
Start Date :
January 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT01505504
Start Date
January 1 2004
End Date
December 1 2011
Last Update
January 6 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Brugmann
Brussels, Belgium, 1020